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microRNAs (miRs) are small, non-coding RNAs, which play crucial roles in the development and progression of 
human cancer. Given that miRs are stable, easy to synthetize and readily introduced into cells, they have been 
viewed as having potential therapeutic benefit in cancer. c-Myc (Myc) is one of the most commonly deregulated 
oncogenic transcription factors and has important roles in the pathogenesis of cancer, thus making it an 
important, albeit elusive therapeutic target. Here we review the miRs that have been identified as being both 
positive and negative targets for Myc and how these participate in the complex phenotypes that arise as a result 
of Myc-driven transformation. We also discussseveral recent reports of Myc-synthetic lethal interactions with 
miRs.These highlight the importance and complexity of miRs in Myc-mediated biological functions and the 
opportunities for Myc-driven human cancer therapies. 
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Introduction 
microRNAs (miRs) are a small class of endogenous 
non-coding RNA molecules that are first transcribed into 
primary miR (pri-miR) products by RNA polymerase II. The 
pri-miRs are then cleaved into precursor miR (pre-miR) by 
the type III RNase Drosha. Following their transport from the 
nucleus to the cytoplasm by Exportin-5/Ran-GTP, pre-miRs 
are processed to double-stranded RNAs by Dicer, another 
type III RNase. After the double-stranded RNAs are 
unwound, individual mature miRs, which are 19-21 nt in 
length, are incorporated into an RNA-induced silencing 
complex (RISC) and bind to the 3’-untranslated region 
(3’UTR) of target mRNAs. These then affect gene 
expression either by inhibiting translation or by promoting 
target degradation[1-3]. It is noteworthy that in most cases, the 
complementarity of miRs to their target sequences is less 
than 100%. As a result, individual miRs can bind imperfectly 
to multiple transcripts with slightly different target sequences 
and affinities and thereby affect multiple cellular 
phenotypes[1-3]. 
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Although many aspects of miR biosynthesis and function 
are understood, there remain a number of questions 
concerning the precise means by which miRs affect gene 
expression.There are several ways by which this is 
accomplished depending on whether their match to 3’UTR 
target gene sequences are perfect or imperfect. These include 
induction of target mRNA degradation, translation-coupled 
protein degradation, inhibition of translation initiation, 
inhibition of translation elongation and termination of 
translation[1-3]. Some miRs can also inhibit mRNA 
processing by interfering with splicing [1-3].The imprecise 
binding of miRs can make the absolute prediction of true 
physiologic target sites challenging. Indeed, target mRNAs 
with otherwise identical miR binding sites can possess 
widely differing degrees of miR binding in an actual cellular 
context and even those targets with similar degrees of miR 
binding can show large variations in response. miRBase, a 
data base for miRs, contains the sequences of more than 
2000 human pri-miR genes and 2588 mature human miR 
sequences; however, the functions for many of these remain 
to be defined. miRs are involved in various normal biological 
processes, such as development, cell growth and metabolic 
programming[3-5]. Loss of control of miR expression can 
contribute to the development of many diseases, including 
cancer[3-6]. Because miRs are very stable, easy to synthetize 
and easily introduced into cells, they have been viewed as 
having therapeutic potential for a wide range of diseases 
including cancer[6-7].  
Differental miR expression patterns between tumors and 
adjacent normal tissues provide useful information for tumor 
classification, prognosis and management[3, 5-7]. Specific 
miRs may display tumor suppressor or oncogenic function. 
For example, the enforced expression of let-7, miR-26 and 
miR-34a can inhibit malignant transformation and 
tumorigenesis whereas enforcing expression ofmiR-21 
promotes B cell lymphomagenesis[3, 5-10]. Altered miR 
expression in cancers canresult from both genetic and 
epigenetic changes. An example of the former is seen with 
deletion of 13q14, which inactivates the tumor suppressors 
miR-15a and miR-16 in chronic lymphocytic leukemia. An 
example of the latter occurs with hypermethylation of CpG 
islands in the promoters of miR-127and miR-124, which 
leads to loss of their tumor suppressorfunction in human 
bladder cancer and hepatocellular carcinoma, respectively[3,
5-10].
c-Myc and miRs
c-Myc (Myc), a helix-loop-helix leucine zipper 
(HLH-ZIP) oncogenic transcription factor, is de-regulated 
and/or over-expressed in a large fractions of human 
malignancies[11-14]. Myc dimerizes with Max, another 
HLH-ZIP protein, and binds to E-box sequences to activate 
transcription of target genes, including somemiRs[11-14]. Myc 
also acts as a transcriptional repressor by interacting with and 
suppressing other transcription factors and/or by modulating 
chromatin status [11-14].Through a myriad of downstream 
targets, Myc supervises a variety of biological processes, 
including cell proliferation, survival, metabolism and 
transformation[11-19]. Over-expressing Myc invarious mouse 
models of cancer causes tumors of a variety of types whereas 
homozygous deletion of Myc is associated with 
developmental abnormalities and embryonic lethality [13,17-19]. 
Homozygous deletion of Myc in rat fibroblasts cells prolongs 
doubling time, indicating that it plays a central role in 
regulating cell proliferation[11-14]. The basis for this involves 
a profound impairment of mitochondrial structure and 
function, which lead to chronic ATP depletion and the 
up-regulation of AMP-activated protein kinase, which 
futilely attempts to restore a normal energy balance by 
suppressing energy-consuming and anabolic processessuch 
as protein translation and proliferation[20]. 
Myc is one of the most frequently altered oncogenes in 
human cancers[15]. Its over-expression occurs as a 
consequence of DNA amplification, chromosomal 
translocation, or protein stabilization either by direct point 
mutations in the Myc protein itself or, more commonly by 
activation of pathways that promote Myc’s 
phosphorylation-dependent stabilization[11-15]. Myc has been 
shown to be necessary for cancer progression and 
maintenance and its up-regulation is often correlated with 
poor clinical outcomes and aggressive cancer phenotypes in 
human neoplasms[21-25]. 
Myc transcriptionally regulates the expression of mRNAs, 
long non-coding RNAs and miRs[12, 26-35]. The latter in 
particular represent an important subset of Myc’s 
transcriptional targets and significantly contribute tothe 
complexity of its function and biological readoutby virtue of 
their post-transcriptional effects on mRNA stability and 
translation[12, 25-35]. Myc can both activate and suppress miR 
expression, thereby regulating a variety of functions 
pertaining to cell growth, apoptosis, metabolic 
re-programming, tumorigenesis, angiogenesis and 
metastasis[25-37]. Myc may also affect the maturation of some 
pri-miRs. In the case of let-7, this occurs indirectly as a result 
of Myc’s up-regulation of the RNA binding proteins Lin-28 
and Lin-28B, which then negatively regulates let-7 [38]. Myc 
and miRs can also reciprocally regulate one another’s 
expression. miRs have been shown to regulate a variety of 
Myc-induced phenotypes[29, 30,34,39]. 
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Table 1. Myc-upregulated miRs 
No. miR Location Targets Function Reference(s) 
1 miR-9 1q22 E-cadherin, E2F1 Proliferation, EMT, survival, 
metastasis 
[40-47] 
2 miR-17 13q31.3 E2F1,TGFBR2, CHEK2, 
TSP1,CTGF 
Migration, tumor growth [27,49-54] 
3 miR-18a 13q31.3 PIAS3, TSP1,CTGF Proliferation, apoptosis  [49-55] 
4 miR-19a 13q31.3 PTEN, BIM, TSP1,CTGF EMT, angiogenesis [49-54,56] 
5 miR-19b 13q31.3 MXD1, TSP1,CTGF Angiogenesis, cell cycle [49-54,56] 
6 miR-20a 13q31.3 E2F1, PTEN, TSP1,CTGF Proliferation, metastasis, 
cell cycle 
[49-54,57] 
7 miR-20b Xq26.2 PTEN, NCOA3, CAPRIN2 Lymphoma progression [49-57] 
8 miR-25 7q22.1 BIM, DR4  Proliferation, apoptosis [58-59] 
9 miR-92a 13q31.3 P57, PTEN Proliferation, cell cycle [49-57] 
10 miR-93 7q22.1 P21 Proliferation, apoptosis [60-63] 
11 miR-106a Xq26.2 PTEN, Hcyp19A1,IRS-2 Growth, metastasis, [63,64] 
12 miR-106b 7q22.1 P21, PTEN Tumorigenesis [58,65] 
13 miR-221 Xp11.3 SOCS3 Migration, invasion [66-67] 
14 miR-378a 5q32 TOB2 Cell growth [30,48] 
Myc-upregulated miRs 
The first reported effect of Myc on miR expression was its 
up-regulation of the polycistronic miR-17-92 cluster[26, 27]. 
Myc induces transcription of pri-17-92 via its direct binding 
to an E-box within the first intron of thepri-17-92 gene. In 
humans, the miR-17-92 cluster is located in an intron of the 
MIR17HG gene located on chromosome 13q31.3. The 
primary pri-17-92 transcript is processed into seven different 
mature miRs: miR-17, miR-18a, miR-19a, miR-19b, 
miR-20a and miR-92a which are widely expressed in 
different tissues and are essential for many developmental 
and pathogenic processes [26, 27]. miR-17-92 deletion in mice 
results in perinatal death due to a combination of severe 
pulmonary hypoplasia and ventricular septal defects. In 
humans, homozygous germ-line deletion of MIR17HG 
significantly reduces mature miR-17-92 levels and is 
associated with a syndrome characterized by microcephaly, 
short stature, and digital defects[40,41]. miR-17-92 acts as an 
oncogene “complex” that regulates multiple cellular 
processes which promote malignant transformation, 
increased survival, rapid proliferation, and 
angiogenesis[28-30,42,43]. miR-17-92 was reported to be 
involved in some human epithelial and hematopoietic 
malignancies. In the latter case, these include neoplasms as 
diverse as diffuse large B-cell lymphoma, Burkitt's 
lymphoma, mantle cell lymphoma, and chronic lymphocytic 
leukemia[28-30,42,43]. A direct role for miR-17-92 in 
lymphomagenesis has been demonstrated by virtue of the 
ability of Eµ-drivenmiR-17-92 in transgenic mice to promote 
the development of B-cell malignancies and massive 
splenomegaly with a high degree of penetrance[30, 42]. 
miR-17-92 appears to promote tumorigenesis by 
antagonizing tumor-suppressing mechanisms, notably 
apoptosis and senescence, through the activities of different 
miR components encoded by this cluster[30, 42]. 
miR-9 expression is also activated by Myc as well as by 
Myc’s close relative N-Myc, both of which bind to a miR-9 
promoter E-box. miR-9 is up-regulated in breast cancer cells 
and directly targets E-cadherin so as to increase cell motility 
and invasiveness[44-47]. 
Interestingly, miR-378 was reported to be a Myc-activated 
miR that can cooperate with activated Ras or HER2/neu to 
promote cellular transformation by directly inhibiting the 
anti-proliferative BTG family member, TOB2, which 
transcriptionally represses the proto-oncogene cyclin D1[48]. 
Additional Myc-upregulated miRs and some of their known 
functions are summarized in Table 1. 
Myc-downregulated miRs 
Although protein-coding gene activation tends to occur 
more commonly than does repression in response to Myc 
activation, the reverse seems to be true for miRs[12,26-37,68]. 
For example, Burkitt’s lymphoma is a highly aggressive 
B-cell neoplasm, which originates from germinal center B 
cells and harbors chromosomal translocations involving Myc 
and immunoglobulin promoter-enhancer loci[69]. Through the 
analysis of human and mouse B cell lymphoma models, 
Chang et al. found Myc to be responsible for the repression 
of multiple miRs, including members of the let-7 and miR-30 
familiesas well as, miR-15a/16, miR-22, miR-26a/b, 
miR-29a/b/c, miR-34a, miR-99a/b, mir-146a, miR-150 and 
miR-195. They found that Myc directly bound to these miR 
promoters, thereby attesting to their direct suppression, and 
that enforced re-expression of the repressed miRs diminished 
the tumorigenic potential of lymphoma cells. This suggested 
that widespread miR repression by Myc contributes to 
tumorigenesis and can be reversed by normalizing the 
expression of at least some miRs[31]. 
In γ-irradiation-induced lymphomas, miR-15a, miR-22, 
miR-23b, miR-125b, miR-26a/b, miR-29a/b and several let-7 
family members have been reported to be repressed in
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Table 2. Myc-downregulated miRs 
No. miR Location Targets Function Reference(s) 







Growth, migration,invasion, EMT [68,69,76] 
2 miR-15a 13q14.2 CCND1,Bcl-2,Bcl-xL, 
YAP1,FOXP3 
Autophagy, proliferation [30,77] 
3 miR-16 13q14.2 CCND1,CCND2, HSP70 Apoptosis, growth, proliferation [30,76,78] 
4 miR-23a 19p13.13 GLS, ABCF1 Metabolism, Chemoresistance [16,79-81] 
5 miR-23b 9q22.32 GLS, Smads,HMGB2 Metabolism, Chemoresistance [16,79,81] 
6 miR-24 9q22.32 OCT4, Smads, DHFR Development, cancer progression [79,80] 
7 miR-26a 3p22.2 EZH2,Lin28B,IL6, HMGA1,EphA2 Proliferation, tumorigenesis,  [70, 82] 
8 miR-27a 19p13.13 FOXO1,Apaf-1,DPD 
Differentiation, metastasis 
[30,80] 
9 miR-27b 9q22.32 ST14, Smads Differentiation,apoptosis [79,80] 
10 miR-28 3q28 Nrf2, MPL, CCND1, HOXB3, 
NM23-H1 
Proliferation, migration [72] 
11 miR-29a/b 7q32.3 CDK6,IGF1R,LAMC1, 
MCL1,AKT2 
Growth,migration [71,76] 
12 miR-30a 6q13 IGF1R, HP1gamma, SOX4, Drp-1 Migration, invasion  [83] 
13 miR-34a 1p36.22 IL6R,HNF4G,cyclin E1 Proliferation, migration, invasion [30,73] 
14 miR-122 18q21.31 IL-1α,DLX4,OCLN Fibrosis, proliferation, metabolism [74] 
15 miR-129-2 11p11.2 PDK4, SOX4,BDKRB2 Migration,chemoresistance [75] 
16 miR-148a 7p15.2 Myc,Wnt1, Dnmt1, IKKβ, LDLR, 
PKM2 
Differentiation, cell cycle [25,30] 
17 miR-185 22q11.21 DNMT1,Myc,SOCS3,VEGFA, 
E2F6,HIF2a 
Proliferation [84] 
18 miR-363 Xq26.2 USP28,S1PR1,E2F3, MBP-1,Mcl-1 Cell cycle,cisplatin-induced apoptosis [25,30] 
19 miR-449a 5q11.2 N-Myc,E2F3,BCL2,
CDC25A,NOTCH1
Survival, cisplatin-induced cytotoxicity, 
invasion, proliferation 
[85] 
response to Myc activation[69]. Restoration of miR-26a 
expression in the cells attenuated cycle progression and 
proliferation by inhibiting the Polycomb complex protein 
EZH2[70]. EZH2 is a histone-lysine N-methyltransferase 
enzyme, which catalyzes the methylation of histone H3 and 
thereby serves to epigenetically repress transcription. 
Presumably, EZH2 down-regulates genes that would 
otherwise prevent transformation and/or proliferation in 
response to Myc de-regulation. 
Along similar lines, Zhang et al. found that miR-29 is 
repressed by Myc through a co-repressor complex comprised 
of EZH2 and histone deacetylase 3 (HDAC3). They showed 
that dual inhibition of HDAC3 and EZH2 disrupted 
theMyc-EZH2-miR-29 axis, leading to restoration of miR-29 
expression, down-regulation of miR-29-targeted genes, and 
lymphoma suppression[33,35,71]. 
miR-28 was also found to be significantly repressed by 
Myc in Burkitt’s lymphoma. Restoring miR-28 expression 
impaired cell proliferation and clonogenicity by inhibiting 
spindle checkpoint proteins including MAD2L1[72 ]. 
In human P-493 B lymphoma and PC3 prostate cells, Myc 
transcriptionally represses miR-23a/b, which can directly 
target mitochondrial glutaminase. This increases glutaminase 
mRNA and protein levels, which promotes glutamine 
catabolism. Glutaminase catalyzes the conversion of 
glutamine to glutamate, which in turn in converted into 
-ketoglutarate, a key TCA cycle substrate that, is also 
needed for nucleotide and amino acid biosynthesis and 
maintenance of redox homeostasis[16]. Increasing the supply 
of -ketoglutarate represents a form of metabolic 
re-programming that may serve to provide substrates to 
mitochondria other than those derived from glucose which 
are increasingly used in support of the Warburg effect [12,16, 
20]. 
Inhibition of miR-34a by Myc is also essential for 
tumorigenesis and survival. Repression of miR-34a was 
shown to be required for IL-6-induced 
epithelial-to-mesenchymal transition (EMT) and invasion. In 
miR-34a-deficient mice, colitis-associated intestinal tumors 
induced by azoxymethane/dextran sodium sulfate showed 
up-regulation of the EMT facilitators p-STAT3, IL-6R and 
SNAIL and progressed to invasive carcinomas [73]. 
Myc is pathologically activated in and essential for 
promoting human hepatocellular carcinoma (HCC)[18, 23-25]. 
In these tumors, Myc represses miR-122 expression directly 
by binding its promoter. Over-expression of miR-122 in 
miR-122-/- hepatocytes was shown to reduce c-Myc protein 
levels, while its depletion in miR-122+/+ hepatocytes led to 
an increase. miR-122 indirectly inhibited Myc transcription 
by targeting Tfdp2 and E2f1 in HCC, both of which bind to 
the Myc promoter and increase transcription. These suggest a 
double-negative feedback loop between miR-122 and 
Myc[74]. 
Similarly, Myc was also found to bind directly to 
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conserved regions in the promoters of miR-148a and 
miR-363 and repress their expression. miR-148a-5p directly 
binds Myc’s 3’UTR and inhibits its expression whereas 
miR-363-3p destabilizes Myc indirectly by inhibiting 
expression of USP28, a Myc deubiquitinase. Together, these 
two miRs provide for a novel and elegant form of positive 
feedback control by which Myc indirectly promotes the 
stabilization of both its own mRNA and protein.The 
importance of these interactions is underscored by the fact 
that inhibition of either miR-148a-5p or miR-363-3p induces 
hepatocarcinogenesis, whereas activation of them has the 
opposite effects[25 ]. 
miR-129-5p is another miR that is transcriptionally 
repressed by Myc. miR-129-5p levels negatively correlate 
with the clinical stage of human HCC and thus with survival. 
Restoring miR-129-5p expression suppresses diethylnitros- 
amine (DEN)-induced hepatocarcinogenesis in mice by 
targeting and down-regulating the activity of pyruvate 
dehydrogenase kinase 4 (PDK4)[75]. PDK4 is a critical 
negative regulator of pyruvate dehydrogenase (PDH), a 
rate-limiting enzyme that connects glycolysis and oxidative 
phosphorylation by converting pyruvate to acetyl coenzyme 
A. PDH’s inhibition via PDK4-mediated phosphorylation
should allow for the accumulation of glycolytic substrates,
and their diversion into the anabolic pathways needed to
support tumor growth. PDK4 inhibition via miR-129-5p
normalizes the flow of pyruvate into the TCA cycle and an
overall inhibition of the Warburg effect by depriving tumor
cells of these critical anabolic substrates. This, along with the
changes in glutamine flow discussed above, represents an
additional Myc-regulated pathway that is responsible for the
metabolic re-programming so commonly associated with
cancer cells[75]. We summarize all the above Myc-suppressed
miRs as well as additional ones in Table 2.
Regulation of Myc expression by miRs 
Myc expression is tightly controlled, both at the 
transcriptional and post-translational level and miRs play 
critical roles in these processes[11-15,28-31]. Some of the 
mechanisms underlying these varied forms of control have 
already been discussed above. 
The first reported Myc-targeting miR was let-7a, which 
down-regulates Myc and reverts Myc-induced growth in 
Burkitt’s lymphoma cells[86,87]. miR-145 was reported to be 
transcriptionally activated by p53 interacting with its 
response element in the miR-145 promoter. Myc is a direct 
target for miR-145. Enforced expression miR-145 silences 
Myc expression while anti-miR-145 enhances its expression. 
miR-145 silencing of Myc expression accounts at least in 
part for the miR-145-mediated tumor cell growth inhibition 
both in vitro and in vivo. miR-145 inhibitionis also able to 
reverse p53-mediated Myc repression[39,88]. 
miR-34a, a positive target of tumor suppressor p53, has 
been reported to function as a tumor suppressor that binds to 
Myc’s 3’UTR and decreases its expression in prostate cancer 
and renal cell carcinoma[89]. In addition to this negative 
regulation of Myc, miR-34a was also found to target FoxM1, 
which, together with Myc, is involved in the activation of 
telomerase reverse transcriptase, which represents the critical 
step in immortalization [90, 91]. It has been shown that 
miR-34b/c’s targeting of Myc requires mitogen-activated 
protein kinase-activated protein kinase 5 (MK5). MK5 
activates miR-34b/c expression via phosphorylation of 
FoxO3a, thereby promoting nuclear localization of FoxO3a 
and enabling it to induce miR-34b/c expression. miR-34b/c 
binds to the 3'UTR of Myc and inhibits its expression. Myc 
in turn directly activates MK5 expression, forming a negative 
feedback loop that is dysregulated in colorectal 
tumorigenesis[92]. 
Interestingly miR-29a was reported to be a tumor 
suppressor that is induced by PRIMA-1Met, a small 
molecule with anti-tumor activity. miR-29a overexpression 
or exposure to PRIMA-1Met reduced multiple myeloma cell 
proliferation by targeting Myc. On the other hand, 
over-expression of Myc at least partially reverted the 
inhibitory effects caused by PRIMA-1Met or miR-29a 
overexpression suggesting that the miR-29a/Myc axis 
mediates anti-myeloma effects of PRIMA-1Met. 
Importantly, intratumoral delivery of miR-29a mimics 
induced regression of tumors in mouse xenograft model of 
MM and this effect synergized with PRIMA-1Met[93]. 
miR-33b is down-regulated in osteosarcoma tumors and 
cell lines and its overexpression significantly inhibits 
proliferation, migration, and invasion of and by 
osteosarcoma cells. Mechanically miR-33b negatively 
regulates Myc at the posttranscriptional level, via a specific 
target site within the 3'UTR. Over-expression of Myc 
impaired miR-33b-induced inhibition of proliferation and 
invasion in osteosarcoma cells. The expression of Myc was 
inversely correlated with miR-33b expression in 
osteosarcoma tumors and cells. Taken together, these 
findings suggest that miR-33b inhibits osteosarcoma cell 
migration and invasion and serves as a tumor suppressor by 
targeting Myc expression [94]. 
miR-130a has also been shown to be a Myc-targeting miR. 
In these studies, ribosomal protein L11 promoted miR-130a’s 
targeting of the 3'-UTR of Myc mRNA thus repressing Myc
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Table 3. Myc-targeting miRs 
No. miR Location Function Cancer type Reference(s) 





Growth, transformation, cisplatin resistance, 
radio-sensitivity, invasion, Differentiation 
Lymphoma, HCC,melanoma,ovarian 
carcinoma, breast cancer, lung 
cancer,medulloblastoma 
[30,69,86,87] 
2 miR-24 9q22.32 Development, cancer progression HCC,lymphoma [96] 
3 miR-29a 7q32.3 Growth, migration, invasion Leukemia, lymphoma, lung cancer [93] 
4 miR-33b 17p11.2 EMT,migration, invasion Melanoma,osteosarcoma [94] 
5 miR-34a 1p36.22 Proliferation, migration, invasion Bladder cancer,sarcomas [30,89-91] 
6 miR-34b/c 11q23.1 Metastasis, EMTgrowth, apoptosis, 
chemo-resistance,self-renewal,  
Colon cancer, breast 
cancer,HCC,renalcancer,lung cancer 
[30,92,97] 
7 miR-125b 11q24.1 Tumor growth, proliferation Breast 
cancer,pancreaticcancer,melanoma,HCC 
[69] 
8 miR-130a 11q12.1 Proliferation,migration,invasion, gefitinib 
resistance 
Breast cancer,HCC, lung cancer [95] 
9 miR-132 17p13.3 Growth, migration, invasion Glioma,lung cancer [69] 
10 miR-135a 3p21.1 Migration, invasion,metastasis Prostate cancer,HCC [98] 
11 miR-145 5q32 Metastasis,invasion Bladder cancer,HCC,prostate cancer [39,88] 
12 miR-148a 7p15.2 Cell cycle, Differentiation HCC, Squamous cell carcinoma [25] 
13 miR-154 14q32.31 Growth, EMT Colorectal cancer,lung cancer, prostate 
cancer. 
[69] 
14 miR-184 15q25.1 Proliferation, invasion Ovarian cancer, glioma,lung cancers [99,100] 
15 miR-320b 1q42.1 Proliferation, invasion Colorectal cancer, [101] 
16 miR-451 17q11.2 Radio-resistance, proliferation Lung, head and neck cancer [102-104] 
17 miR-494 14q32.31 Growth, proliferation, cell cycle Gastric carcinoma, lymphoma, HCC, 
ovarian cancer 
[105-107] 
18 miR-744 17p12 Proliferation HCC [108] 
Expressionin response to UV irradiation. miR-130a 
overexpression promoted Ago2 binding to Myc mRNA, 
significantly reduced the levels of both Myc mRNA and 
protein and inhibited cell proliferation. UV treatment 
markedly enhanced the binding of L11 to miR-130a, Myc 
mRNA and Ago2 in cells. Inhibiting miR-130a significantly 
suppressed UV-mediated Myc reduction. L11 was 
re-localized from the nucleolus to the cytoplasm where it 
associated with Myc mRNA upon UV treatment. These 
findings reveal a novel mechanism underlying Myc 
down-regulation in response to UV-mediated DNA 
damage[95]. Interestingly miR-24 inhibited Myc expression 
by recognizing seedless but highly complementary 3'-UTR 
sequences[96]. All known Myc-targeting miRs are listed in 
Table 3. 
Myc-synthetic lethal interactions 
In some murine models of Myc-dependent cancers, the 
suppression of Myc leads to tumor regression, thus indicating 
that continuous Myc expression is necessary to maintain 
tumor growth and/or viability[11-13,18]. Myc’s role in the 
pathogenesis of cancer and the apparent “addiction” of some 
cancer to continuous Myc expression makes it an enticing, 
albeit elusive chemotherapeutic target[11-13,18,109-113]. 
Strategies aimed at inhibiting Myc itself including antisense 
oligodeoxy nucleotides and RNAi, small molecule disruptors 
of the Myc-Max heterodimer and inhibitors of chromatin 
modifying complexes with which Myc associates have been 
investigated as options for attacking Myc-driven 
cancers[11-13,18,109-120]. However these attempts to 
pharmacologically inhibit Myc have remained, to various 
degrees, ineffective and/or non-specific[109-120]. 
Because Myc is essential for the growth of some normal 
as well as transformed cells, it has sometimes been viewed as 
being a poor therapeutic target given that the protein is also 
seldom mutated in cancer and possesses no obviously 
“druggable” domains or enzymatic activity[11-13,109,110,113]. 
Thus it has been suggested that taking advantage of Myc’s 
synthetic lethal interactions could be exploited as an effective 
therapeutic strategy in Myc-driven human 
cancers[109,110,112,121-137]. 
A synthetic lethal interaction is defined as a combination 
of two mutations that confers lethality to a cell without either 
individual mutation alone having such an 
effect[109,110,112,121-127]. A classical example of synthetic 
lethality is seen with the use of poly ADP-ribose polymerase 
(PARP) inhibitors to treat BRCA1- and BRCA2-deficient 
breast cancers. The inability of these cancers to repair 
damaged DNA in response to PARP inhibition occurs only in 
tumor cells that are defective in BRCA1/2-mediated DNA 
repair and not in otherwise normal cells[121-125]. Because 
tumor cells contain numerous genetic, epigenetic and 
metabolic alterations, a large number of heterogenous 
synthetic lethal genes have been identified whose inhibition 
confers synthetic lethality[109,110,112,121-127]. Among the 
molecules that have been used to identify synthetic lethal 
targets, both in vitro and in vivo, are low molecular weight 
drug-like compounds, siRNA/shRNAs, CRISPRs and 
miRs[109,110,112,121-127].  
Previous siRNA/shRNA screens for Myc-synthetic lethal 
have identified regulators of the Myc network, components
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Table 4. Summary of synthetic lethal targets of Myc oncogene 
No. Genes Location Function Reference 
1 AURKB 17p13.1 Cell division [134] 
2 BUD31 7q22.1 RNA splicing [128,129] 
3 CDK1 10q21.1 Cell cycle [131,132] 
4 CDK9 9q34.1 Transcription elongation [133] 
5 DR5 8p22-p21 Cell death [135] 
6 EIF4F 4q23 Protein synthesis [136] 
7 MAP3K13 3q27 Protein kinase [137] 
8 miR-206 6p12.2 Tumor suppressor miR [137] 
9 SAE2 18q11.2 Sumoylation/DNA repair [130] 
10 SF3B1 2q33.1 RNA splicing [128,129] 
11 U2AF1 21q22.3 RNA splicing [128,129] 
of RNA transcription initiation and elongation, proteins 
involved in sumoylation and ubiquitylation and kinases with 
roles in DNA repair and cell cycle 
checkpoints[109,110,112,128-137]. More recently, the spliceosome 
was discoveredto be a new target of oncogenic stress in 
Myc-driven cancers. BUD31, a core component of the 
spliceosome, was identified as a Myc synthetic lethal gene in 
human mammary epithelial cells. Other core spliceosome 
factors that interact with BUD31, such U2AF1 and SF3B1, 
were also identified as Myc synthetic lethals. Myc 
hyperactivation increases the total cellular burden of 
precursor mRNA synthesis, thus likely placing greater 
demands and stress on the pre-RNA processing function of 
spliceosomes. In contrast to normal cells, partial inhibition of 
the spliceosome in Myc-hyperactivated cells was found to be 
associated with global intron retention, widespread defects in 
pre-mRNA maturation and deregulation of many essential 
cell processes. Genetic or pharmacological inhibition of the 
spliceosome in vivo also impaired survival, tumorigenicity 
and metastatic proclivity of breast cancers with high Myc 
level but had a less pronounced effect in tumors with lower 
Myc levels. Collectively, these findings suggest that 
oncogenic Myc confers a collateral stress on splicing, and 
that components of the spliceosome may be viable synthetic 
lethal therapeutic targets for Myc-driven cancers[128,129]. 
SAE2, an endonuclease that plays an important role in 
DNA repair and that is necessary for the growth of cancers 
with high Myc levels, has also been shown to interact with 
de-regulated Myc in a synthetic lethal manner[130]. 
Inhibition of some cyclin-dependent kinases was also 
reported to be selectively toxic in breast cancers with high 
Myc levels [131-133]. For example, CDK9 is a component of 
the Myc-regulated RNA polymerase II-directed 
transcriptional elongation machinery and functions to 
phosphorylate the C-terminal domain of RNA polymerase 
II’s largest subunit[133]. Myc-synthetic lethal genes are 
summarized in Table 4. 
A few reports have used miRs to identify synthetic lethal 
relationships in cancer cells that over-express Myc or other 
oncogenes. By functionally screening a miR library 
comprised of 1254 individual miR expression vector, we 
identified miR-206 as being able to impart a synthetic lethal 
phenotype in Myc over-expressing human cancer cells[137]. 
miR-206had similar growth inhibitory effects on both the in 
vitro and in vivo proliferation of breast cancer cells, but only 
when they expressed high levels of Myc as would be 
expected of a classic synthetic lethal relationship. This 
appeared to be dependent on miR-206’s ability to target 
MAP3K13 as indicated by the ability to recapitulate similar 
phenotypes by suppressing MAPK3K13 through other 
means, including two different shRNAs. 
Bioinformatics-based analyses of gene expression profiles 
from the TCGA collection of breast cancers indicated that 
those tumors with the highest Myc levels tended to express 
the lowest levels of miR-206 and the highest levels of 
MAP3K13 while simultaneously being associated with more 
adverse clinical outcomes. The critical link between miR-206 
and MAP3K13 in the development of Myc over-expressing 
human cancers suggested potential points of therapeutic 
intervention for this molecular sub-category.These results 
showed that MAP3K13 and perhaps downstream targets of 
MAP3K13 such as members of the JNK signaling pathway 
are Myc-synthetic lethal targets[137]. 
Future directions 
The direct inhibition of certain“undruggable”oncoproteins, 
such as Myc remains an elusive goal in cancer therapy. As a 
way of circumventing this problem, synthetic lethal 
interactions could be exploited as an alternate therapeutic 
strategy, thus avoiding the inherent complexities of direct 
Myc inhibition. Given that miRs are easy to synthetize and 
can be readily introduced into cells, they possess significant 
potential for cancer therapy. Alternatively, even easier and 
more direct approaches could be envisioned in cases where 
the synthetic lethal genes identified by such screens encoded 
enzymes for which small molecule inhibitors could be 
generated. Such small molecules could then be used as 
substitutes for miRs or perhaps even in combination. miRs 
thus have potential not only as therapeutic entities but as 
tools to drive the ongoing discovery of new synthetic lethal 
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interactions. Many approaches to identify synthetic lethal 
interactions have been successfully developed. Currently, 
most screens continue to be performed in vitro using cultured 
cells, primarily because of the relative ease and directness of 
high throughput as well as the potential for 
multiplexed-based screens. The latter are likely to grow in 
popularity, given the ease with which such screens can now 
be combined withdeep sequencing-based approaches to 
identify relevant miRs or shRNAs that have been selectively 
depleted from complex libraries. The potential for screening 
in vivo using tractable organisms such as zebrafish are also 
high and further promises to reduce the time needed to 
identify promising hits, characterize their mechanisms of 
action and proceed to clinical trials[138, 139]. 
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